Patent Classification

Drug Delivery System, Transcorneal

1. Transcorneal drug-release system

Drug Delivery System, Transdermal/Percutaneous

1. Transdermal compositions
    
2. Percutaneous delivery system for treatment of osteonecrosis of the hip and methods of use thereof
    
3. Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisions
    
4. Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
    
5. Transdermal device having mechanical assist for porator-to-skin contact
    
6. Transdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
    
7. Transdermal pharmaceutical composition
    
8. Transdermal delivery system of diclofenac with improved water absorbability and adhesion properties
    
9. Film base material for adhesive skin patch and adhesive skin patch
    
10. Topical preparation and method for transdermal delivery and localization of therapeutic agents
     
11. Adhesive mixture for transdermal delivery of highly plasticizing drugs
     
12. Pharmaceutical composition for transdermal or transmucous administration
     
13. Needle-free administration of FeLV vaccines
     
14. Formulations for coated microprojections containing non-volatile counterions
     
15. Drug delivery system for accelerated subcutaneous absorption
     
16. Apparatus and method for transdermal delivery of parathyroid hormone agents 
     
17. Preparations for percutaneous absorption
     
18. Patch material for ionic medicine administration
     
19. Method for the improvement of transport across adaptable semi-permeable barriers
     
20. Adhesive for percutaneous absorption, adhesive composition for percutaneous absorption and preparation for percutaneous absorption
     
21. Topical and transdermal treatments using urea formulations
     
22. Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
     
23. Dermal penetration enhancers and drug delivery systems involving same
     
24. Permeation enhancing compositions for anticholinergic agents
     
25. Transdermal therapeutic system for treating Parkinsonism
     
26. Transdermal therapeutic system comprising a reservoir type pressure sensitive adhesive layer and a back layer with uni-directional resilience
     
27. Transdermal delivery system for dried particulate or lyophilized medications
     
28. Transdermal delivery system for dried particulate or lyophilized medications
     
29. Induction of a protective immune response through microprojectiles coated with a DNA sequence encoding an immunogenic protein
     
30. Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole
     
31. Transdermal delivery system for dried particulate or lyophilized medications
     
32. Transdermal therapeutic system for administering non-steroidal antiphlogistic agents containing carboxyl groups, and a method for the production of the same
     
33. Transdermal warfarin system
     
34. Mixture for transdermal delivery of low and high molecular weight compounds
     
35. Alcohol-free transdermal insulin composition
     
36. Transdermal buprenorphine dosage regimen for analgesia
     
37. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
     
38. Compositions and medical device for transdermal delivery of a drug and methods of making and using same
     
39. Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
     
40. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
     
41. Formulations for topical delivery of bioactive substances and methods for their use
     
42. Mixture for transdermal delivery of low and high molecular weight compounds
     
43. Formulations for transdermal or transmucosal application
     
44. Therapeutic system which can be moisture-activated
     
45. Penetration enhancing and irritation reducing systems
     
46. Adhesive mixture for transdermal delivery of highly plasticizing drugs
     
47. Transdermal thermal polymerization
     
48. Compositions for drug administration by electroporation
     
49. Adhesive mixture for transdermal delivery of highly plasticizing drugs
     
50. Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
     
51. Adjuvant for transcutaneous immunization
     
52. Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
     
53. Hydrogel particle formulation
     
54. Felodipine transdermal device and methods
     
55. Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
     
56. Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
     
57. Skin penetration enhancing components
     
58. Tape material for transcutaneous absorption
     
59. Transdermal delivery system
     
60. Methods compositions and devices utilizing stinging cells/capsules for delivering therapeutic or a cosmetic agent into a tissue
     
61. Ultraviolet-screening patch
     
62. Laminates containing an active substance transdermal system
     
63. Transdermal therapeutic system containing hormones and crystallization inhibitors
     
64. Transdermal delivery system for alkaloids of aconitum species
     
65. Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
     
66. Topical transdermal treatments
     
67. Compositions and methods for topical delivery of oligonucleotides
     
68. Dual enhancer composition for topical and transdermal drug delivery
     
69. Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience
     
70. Transdermal administration of ACE inhibitors
     
71. Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
     
72. Transdermal therapeutic system TTS containing tolterodine
     
73. Mixture for transdermal delivery of low and high molecular weight compounds
     
74. Controlled heat induced rapid delivery of pharmaceuticals from skin depot
     
75. Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties
     
76. Methods and apparatus for improved administration of testosterone pharmaceuticals
     
77. Percutaneous absorption promoters for electroporation
     
78. Transdermal delivery of an anti-inflammatory composition
     
79. Transdermal and topical administration of local anesthetic agents using basic enhancers
     
80. Transdermal delivery system
     
81. Active substance patch, kind to the skin, for transdermal administration of nonsteroidal antirheumatics
     
82. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
     
83. Solution-based transdermal drug delivery system
     
84. Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
     
85. Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-.beta.-estradiol to the human organism
     
86. Transdermally administered acetylcysteine as mucolytic agent
     
87. Electrical apparatus for heating to a desired temperature for improved administration of pharmaceutically active compounds
     
88. Administration of oxazolidinones for transdermal delivery
     
89. Elevation of circulating blood histamine levels
     
90. Transdermal administration of phenylpropanolamine
     
91. Pharmaceutical composition containing two active ingredients for smoking cessation
     
92. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
     
93. Therapeutical system for transdermal delivery of levonorgestrel
     
94. Pharmaceutical dosage form for transdermal administration
     
95. Estradiol-containing patch for transdermal application of hormones
     
96. Transdermal therapeutic system containing estradiol
     
97. Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
     
98. Nicotine delivery compositions
     
99. Transdermal patch for nonsteroidal antiinflammatory drug(s)
     
100. Hot melt adhesives for dermal application
      
101. Ultrasound enhancement of percutaneous drug absorption
     
     
102. Transdermal preparation contacting a loratidine metabolite with antihistaminic activity
     
     
103. Method and devices for transdermal delivery of lithium
     
     
104. Anhydrous drug reservoir for electrolytic transdermal delivery device
     
     
105. System for percutaneous delivery of opioid analgesics
     
     
106. Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease
     
     
107. Method of treating HIV infection with transdermal gel containing mammalian liver extract
     
     
108. Transdermal absorption of active substances from subcooled melts
     
     
109. Method for reducing onset time of pharmaceutically active compounds
      
     
110. Pressure sensitive adhesive compositions for transdermal drug delivery devices
      
     
111. Transdermally administered dextromethorphan as antitussive agent
      
     
112. Cannabinoid patch and method for cannabis transdermal delivery
      
     
113. Penetration enhancing and irritation reducing systems
      
     
114. Isosorbide dinitrate-containing patch
      
     
115. Patch and method for transdermal delivery of bupropion base
      
     
116. Apparatus for heating to a desired temperature for improved administration of pharmaceutically active compounds
      
     
117. Transdermally administrable medicament with ACE inhibitors
      
     
118. Methods and apparatus for improved administration of pharmaceutically active compounds
      
     
119. Enhanced transdermal anesthesia of local anesthetic agents
      
     
120. Formulation for electrically assisted delivery of lidocaine and epinephrine
      
     
121. Method and composition for transdermal administration of pharmacologic agents
      
     
122. Methods and apparatus for improved administration of fentanyl and sufentanil
      
     
123. Method for transdermal application of active substances at high constant dosage
      
     
124. Enhanced skin penetration system for improved topical delivery of drugs
      
     
125. Transdermal, hormone-delivering therapeutic system
      
     
126. Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
      
     
127. Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
      
     
128. Transdermal drug patch with attached pocket for controlled heating device
      
     
129. Composition for transdermal delivery of drugs
      
     
130. Pharmaceutical composition containing acid addition salt of basic drug
      
     
131. Methods and apparatus for improved administration of pharmaceutically active compounds
      
     
132. Transdermal administration of fenoldopam
      
     
133. Solubility parameter based drug delivery system and method for altering drug saturation concentration
      
     
134. Composition for controlled and sustained transdermal administration
      
     
135. Device for enhancing transdermal agent delivery or sampling
      
     
136. Transdermal application of naturally occurring steroid hormones
      
     
137. Sealing bag for a transdermal therapeutic system
      
     
138. Solubility parameter based drug delivery system and method for altering drug saturation concentration
      
     
139. Adhesive patch for lithium controlled release
      
     
140. Reduction of skin reactions caused by transdermal drug delivery
      
     
141. Device for the transdermal delivery of diclofenac
      
     
142. Hydrophilic pressure sensitive hot-melt adhesives
      
     
143. Carrier patch for the delivery of agents to the skin
      
     
144. Patch preparations for percutaneous absorption
      
     
145. Methods and apparatus for treatment of Parkinson's disease
      
     
146. Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers
      
     
147. Patch applicator
      
     
148. Method for the low-waste manufacture of diskoid moulded bodies containing active ingredients, and transdermal therapeutic systems containing same
      
     
149. Solid matrix system for transdermal drug delivery
      
     
150. Percutaneous absorption preparation
      
     
151. Method for the application of an active substance patch for controlling or alleviating an addiction
      
     
152. Transdermal therapeutic system, its use and production process
      
     
153. Composition for the transdermal delivery of lerisetron
      
     
154. Transdermal device for the delivery of testosterone
      
     
155. Patch applicator
      
     
156. Transdermal therapeutic system, its use and production process (Patent 6,126,963)
      
     
157. Transdermal therapeutic system, its use and production process (Patent 6,117,448)
      
     
158. Iontophoretic transdermal delivery device
      
     
159. Topical and transdermal delivery system utilizing submicron oil spheres
      
     
160. Cannabinoid patch and method for cannabis transdermal delivery
      
     
161. Transdermal therapeutic system, its use and production process
      
     
162. Adhesive patch for applying medication to the skin and method
      
     
163. Compliance verification method and device in compulsory drug administration
      
     
164. Estradiol penetration enhancers
      
     
165. Buprenorphine percutaneous absorption preparation
      
     
166. Drug delivery device
      
     
167. Transdermal therapeutic system identified without printing inks
      
     
168. Percutaneous preparation
      
     
169. Transdermal therapeutic system for administering active agents to the human body via the skin
      
     
170. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
      
     
171. Extrudable compositions for topical or transdermal drug delivery
      
     
172. Temporally controlled drug delivery systems
      
     
173. Adhesive binders for dermal or transdermal therapy systems
      
     
174. Method for producing transdermal patches (TTS)
      
     
175. Composition for skin patch preparation and process for preparing the same
      
     
176. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
      
     
177. Drug preparations for treating sexual dysfunction
      
     
178. Intersorption composition and method
      
     
179. Composition and methods for transdermal delivery of acid labile drugs
      
     
180. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
      
     
181. Solubility parameter based drug delivery system and method for altering drug saturation concentration
      
     
182. Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
      
     
183. Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
      
     
184. Penetration enhancement of topically applied therapeutic formulations
      
     
185. In vivo and in vitro model of cutaneous photoaging
      
     
186. Transdermal matrix system
      
     
187. Transdermal patch incorporating a polymer film incorporated with an active agent
      
     
188. Transdermal matrix system
      
     
189. Transdermal vasodilator (*Large document -- long loading time)
      
     
190. Automated transdermal drug delivery system
      
     
191. Topical and transdermal delivery system utilizing submicron oil spheres
      
     
192. Permeation enhances for transdermal drug delivery compositions, devices and methods
      
     
193. Use of starch for transdermal applications
      
     
194. Formulations for transdermal delivery of pergolide
      
     
195. Transdermal protein delivery using low-frequency sonophoresis
      
     
196. Process for the production of a transdermal therapeutic system comprising the active substance 17-.beta.-estradiol (anhydrous)
      
     
197. Hydrophilic adhesive and binder for medications
      
     
198. Biphasic lipid vesicle composition for transdermal administration of an immunogen
      
     
199. Transdermal therapeutic system (TTS) containing vitamin E for the treatment of drug dependency
      
     
200. System for transdermal delivery of pain relieving substances
      
     
201. Transdermal hormone patch
      
     
202. Composition and method of enhancing electrotransport agent delivery
      
     
203. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
      
     
204. Transdermal formulation of xanomeline 
      
     
205. Solid matrix system for transdermal drug delivery
      
     
206. Transdermal nicotine metabolites and human body weight
      
     
207. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
      
     
208. Adhesive matrix type transdermal patch and method of manufacturing same
      
     
209. Solubility parameter based drug delivery system and method for altering drug saturation concentration
      
     
210. Adhesive matrix type transdermal patch and method of manufacturing same
      
     
211. Fatty acid esters of lactic acid salts as permeation enhancers
      
     
212. Transdermal pressure sensitive adhesive drug delivery system
      
     
213. Transdermal patch
      
     
214. Transdermal administration of apomorphine
       
     
215. Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman
      
     
216. Iontophoretic delivery of cell adhesion inhibitors
      
     
217. Transdermal therapeutic system with protection against hydrolysis
      
     
218. Multidose transdermal drug delivery system
      
     
219. Monolithic matrix transdermal delivery system for administering molsidomine

Drug Delivery System, Transepithelial

1. Receptor specific transepithelial transport of therapeutics
    
2. Transepithelial transport of molecular species
    
3. Receptor specific transepithelial transport of therapeutics

Drug Delivery System, Transfection/Targeted, Nucleic Acid/Gene

1. Ocular gene therapy using avalanche-mediated transfection
    
2. Transfection kinetics and structural promoters
    
3. Sustained DNA delivery from structural matrices
    
4. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
    
5. In vivo production and delivery of erythropoietin or insulinotropin for gene therapy
    
6. Transfection agents
    
7. AAV virions with decreased immunoreactivity and uses therefor
    
8. Nucleic acid transfer complexes
    
9. Compositions for receptor/liposome mediated transfection and methods of using same
    
10. Methods for enhanced retroviral-mediated gene transfer
     
11. Methods for transfecting T cells
     
12. Methods and compositions for enhancing the delivery of a nucleic acid to a cell
     
13. Methods for encapsulating plasmids in lipid bilayers
     
14. Synthetic transfection vectors
     
15. Methods for compositions for in vivo gene delivery
     
16. High efficiency transfection based on low electric field strength, long pulse length
     
17. Sequence and method for genetic engineering of proteins with cell membrane translocating activity
     
18. Process for generating multilayered particles
     
19. Use of lithium (Li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
     
20. Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains
     
21. Method for treatment of an aqueous flux by electropulsation of a field parallel to the flow, pulsation chamber and uses thereof
     
22. Method for nucleic acid transfection of cells
     
23. Compositions for receptor/liposome mediated transfection and methods of using same
     
24. Use of G-actin for improving transfection of a polynucleotide into a cell
     
25. Targeted gene delivery system
    
    
26. Method for nucleic acid transfection of cells
    
    
27. Targeting gene expression to living tissue using jet injection
    
    
28. Integrative protein-DNA cochleate formulations and methods for transforming cells
     
    
29. Episomal expression vector for human gene therapy
     
    
30. Acid salts of cholesterol
     
    
31. Genetically engineered retroviral vector particles capable of infecting non-dividing cells
     
32. Composition for introducing nucleic acid complexes into higher eucaryotic cells
     
    
33. Enhanced expression of transgenes
     
    
34. Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
     
    
35. Methods of forming protein-linked lipidic microparticles, and compositions thereof
     
    
36. Biodegradable mixed polymeric micelles for gene delivery
     
    
37. Gene expression in mammalian cells
     
    
38. Methods for the intracellular delivery of substances
     
    
39. Synthetic transfection vectors
     
    
40. Materials and methods for delivery and expression of heterologous DNA in vertebrate cells
     
    
41. Self-assembling polynucleotide delivery system comprising dendrimer polycations
     
    
42. Liposome-mediated transfection of central nervous system cells

Drug Delivery System, Transplacental

1. Transplacental delivery of oligonucleotides

Drug Delivery System, Ultrasound/Electromagnetic

1. Therapeutic ultrasound gel
    
2. Ultrasonic concentration of drug delivery capsules
    
3. Delivery of pharmaceutical compounds and collection of biomolecules using electromagnetic energy and uses thereof
    
4. Ultrasound enhancement of percutaneous drug absorption
   
   
5. Apparatus and method for the local delivery of drugs
   
   
6. Delivery of biologically active substance to target sites in the body of patients

Drug Delivery System, Vector, Viral/Bacterial/Synthetic

1. AAV vectors produced in insect cells
    
2. Selectively replicating viral vectors
    
3. Expression vectors with improved safety
    
4. Recombinant mononegaviral virus vectors
    
5. Chimeric adenoviral vectors
    
6. Tetracycline-regulated adeno-associated viral (AAV) vectors for gene delivery to the nervous system
    
7. Vectors comprising CpG islands without position effect varigation and having increased expression
    
8. Virus envelope vector for gene transfer
    
9. Primate T-lymphotropic viruses
    
10. Cell-specific expression/replication vector
     
11. Methods of gene transfer to astrocytes with mokola virus pseudotyped lentivirus vectors
     
12. Cumate-inducible expression system for eukaryotic cells
     
13. Vectors with modified protease-dependent tropism
     
14. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions
     
15. PAV regions for encapsidation and E1 transcriptional control
     
16. Bovine immunodeficiency virus (BIV) based vectors
     
17. Compositions and methods for systemic nucleic acid sequence delivery
     
18. Signal for packaging of influenza virus vector
     
19. Chimeric flavivirus vectors
     
20. Structural protein of adeno-associated virus with modified antigenicity, its production and its use
     
21. Photochemical internalization for virus-mediated molecule delivery into the cyosol
     
22. Method for introducing a biological molecule using a viral envelope and heparin and system therefore
     
23. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
     
24. Means and methods for the production of adenovirus vectors
     
25. Viral vectors for gene therapy
     
26. Tetracycline-regulated adeno-associated viral (AAV) vectors for gene delivery to the nervous system
     
27. Method for the production and purification of adenoviral vectors
     
28. Recombinant sendai virus
     
29. Use of vaccinia virus deleted for the E3L gene as a vaccine vector
     
30. Method of producing infectious reovirus
     
31. Vector system
     
32. Antigen transduced T cells used as a delivery system for antigens
     
33. Transgenic algae for delivering antigens to an animal
     
34. Host cells comprising cDNA corresponding to the antigenome of nonsegmented negative strand RNA viruses, further encoding antigenically active proteins
     
35. Vectors with modified protease-dependent tropism
     
36. Synthetic gagpol genes and their uses
     
37. Tumor-specific vector for gene therapy
     
38. Methods of adenovirus production
     
39. Method of determining adenovirus particle concentration
     
40. Method of effecting a change in a cell, and a vector
     
41. AAv scleroprotein, production and use thereof
     
42. Regulatory elements for delivery to the liver
     
43. Stable episomal vectors
     
44. Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
     
45. Vector system
     
46. Parvovirus vectors and their use
     
47. Cell lines for the propagation of mutated herpes viruses
     
48. Adenoviral vector with replication-dependent transgene expression
     
49. Self-rearranging DNA vectors
     
50. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
     
51. High capacity recombinant adenoviral vector for treatment of hemophilia A
     
52. Means and methods for fibroblast-like or macrophage-like cell transduction
     
53. Bacterial delivery system
     
54. Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
     
55. Signal for packaging of influenza virus vectors
     
56. Bovine immunodeficiency virus (BIV) based vectors
     
57. Virus vectors and methods of making and administering the same
     
58. Hyaluronic acid mediated adenoviral transduction
     
59. Plasmid maintenance system for antigen delivery
     
60. Bovine immunodeficiency virus (BIV) based vectors
     
61. Method for the production and purification of adenoviral vectors
     
62. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
     
63. Vesicular monoamine transporter gene therapy in parkinson's disease
     
64. Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
     
65. Targeted retrograde gene delivery to motor neurons
     
66. Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
     
67. Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
     
68. Retroviral vectors including modified envelope escort proteins
     
69. Retroviral vectors with foreign-sequence insertion between retroviral primer binding site and retroviral splice donor
     
70. Defective adenoviruses and corresponding complementation lines
     
71. Vectors for animal cells and utilization thereof
     
72. Inducible expression vectors and methods of use thereof
     
73. Packaging systems for human recombinant adenovirus to be used in gene therapy
     
74. Sequences for targeting metastatic cells
     
75. Particles for gene therapy
     
76. Compositions comprising tissue specific adenoviral vectors
     
77. Vector for reversible gene integration
     
78. Recombinant adenoviral vector and methods of use
     
79. Vectors derived from South African Arbovirus No. 86
     
80. Vector for the expression of two foreign genes
     
81. Circular DNA molecule with conditional origin of replication, method for preparing the same and use thereof in gene therapy
     
82. Methods for producing high titre vectors and compositions used in such methods
     
83. Methods and reagents for the detection of antibodies to adenovirus
     
84. Compositions and methods for tumor-targeted delivery of effector molecules
     
85. AAV2 vectors and methods
     
86. Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain
     
87. Recombinant bacterial cells for delivery of PNP to tumor cells
     
88. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
     
89. Compositions and methods for helper-free production of recombinant adeno-associated viruses
     
90. Vectors and methods for gene transfer
     
91. Replicating adenovirus vectors
     
92. Antitumour vector constructs and methods
     
93. Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
     
94. Tumour-specific vector for gene therapy
     
95. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
     
96. Adenovirus vector
     
97. Virus envelope vector for gene transfer
     
98. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
     
99. Method of preparing a eukaryotic viral vector
     
100. Gene delivery vectors with cell type specificity for mesenchymal stem cells
      
101. Retroviral vectors, methods for their preparation and their use for gene transfer into CD4-positive cells
      
102. Gene delivery system and methods of use
      
103. Controlled surface-associated delivery of genes and oligonucleotides
      
104. Gene therapy vehicle comprising dermal sheath tissue
      
105. Antitumoral composition based on immunogenic polypeptide with modified cell location
      
106. Packaging systems for human recombinant adenovirus to be used in gene therapy
      
107. Methods and compositions for efficient gene transfer using transcomplementary vectors
      
108. Monocyte-specific particulate delivery vehicle
      
109. Bovine immunodeficiency virus (BIV) based vectors
      
110. Methods and compositions for increasing the infectivity of gene transfer vectors
      
111. Tumor targeted vector
      
112. Site specific recombinase based method for producing adenoviral vectors
      
113. In vitro construction of SV40 viruses and pseudoviruses
      
114. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
      
115. Replication incompetent herpes viruses for use in gene therapy
      
116. Vectors and methods for immunization or therapeutic protocols
      
117. Retroviral delivery system
      
118. Synthetic transfection vectors
      
119. VZV ORF29p protein-related compositions and methods
      
120. Method for the identification of a receptor
      
121. Gene delivery vectors with cell type specificity for primary human chondrocytes
      
122. Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells and therapeutic uses thereof
      
123. Adenovirus carrying gag gene HIV vaccine
      
124. Encapsulated cells producing viral particles
      
125. Method for the quantitation of alphavirus replicon particles
      
126. Herpes simplex virus expressing foreign genes and method for treating cancers therewith
      
127. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
      
128. Vectors including foreign genes and negative selective markers
      
129. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain
      
130. Viral vectors having reduced virulence
      
131. Paramyxovirus vectors used for transfer of foreign genes
      
132. Viral recombinant vectors for expression in muscle cells
      
133. Recombinant adenovirus
      
134. Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
      
135. Vectors that repress heterologous promoter activity
      
136. Mutant herpes simplex viruses and uses thereof
      
137. Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein
      
138. Packaging systems for human recombinant adenovirus to be used in gene therapy
      
139. Controlling immune response to specific antigens
      
140. Vectors for the diagnosis and treatment of solid tumors including melanoma
      
141. Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
      
142. Poliovirus replicons encoding therapeutic agents and uses thereof
      
143. Triple hybrid amplicon vector systems to generate retroviral packaging lines
      
144. Herpes simplex virus amplicon vector targeting system and method of using same
      
145. Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains
      
146. Targeting adenovirus with use of constrained peptide motifs
      
147. Herpes virus vectors for dendritic cells
      
148. Tissue-vectors specific replication and gene expression
      
149. Targeted vectors
      
150. Adenoviral-vector-mediated gene transfer into medullary motor neurons
      
151. Temperature-sensitive regulation of viral vector production
      
152. HSV viral vector
      
153. Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
      
154. Adenoviral vectors with tandem fiber proteins
      
155. Methods of administering adenoviral vectors
      
156. Metabolically activated recombinant viral vectors and methods for the preparation and use
      
157. System for the in vivo delivery and expression of heterologous genes in the bone marrow
      
158. Hybrid vectors for gene therapy
      
159. Chimeric viral packaging signal without gag gene sequences
      
160. Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
      
161. Insertional mutations in mycobacteria
      
162. Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
      
163. Complex of biotinylated viral vector and ligand for targeted gene delivery
      
164. Retroviral gene transfer vectors
      
165. Retroviral gene therapy vectors and therapeutic methods based thereon
      
166. Adenoviral helper vectors
      
167. Adenoviral vectors encoding a cytokine and a conditionally lethal gene
      
168. Invasive bacterial vectors for expressing alphavirus replicons
      
169. Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus
      
170. Lentivirus-based gene transfer vectors
      
171. Viral vector complexes having adapters of predefined valence
      
172. Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
      
173. Methods of administering adenoviral vectors
      
174. Recombinant AAV packaging systems
      
175. Recombinant adenoviral vectors comprising a splicing sequence 
     
     
176. Use of herpes vectors for tumor therapy
     
     
177. Cloning vector
      
     
178. Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof

Drug Delivery System, Veterinary

1. Marek's disease virus vaccine
    
2. Trace elements
    
3. Methods and vaccines for providing in ovo protection against turkey rhinotracheitis
    
4. Cationic lipid-mediated enhancement of nucleic acid immunization of cats
    
5. Pediculocidal and veterinary compositions
    
   
6. Delivery system for antimethanogenic agents
    
   
7. Live in ovo vaccine
    
   
8. Altering sex ratio of offspring in mammals
    
   
9. Method for supplying bioavailable methionine to a cow
    
   
10. Use of pharmaceutical composition in the treatment of traumatic arthritis in horses
     
    
11. Hydrophilic polymer blends used to prevent cow skin infections
     
    
12. DNA based vaccination of fish
     
    
13. Edible anti-parasite medication for domesticated animals
     
    
14. Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
     
    
15. Digestible pouch and method for administering medications to an animal
     
    
16. Administration of an injectable antibiotic in the ear of an animal
     
    
17. Vaccines for equine influenza
     
    
18. Composition and system for oral administration to animals (*Large document -- long loading time)

Drug Delivery System, Water, Sparingly Soluble

1. Compositions and methods for preparation of poorly water soluble drugs with increased stability
    
2. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
    
3. Aqueous solubility pharmaceutical formulations
    
4. Stable complexes of poorly soluble compounds in ionic polymers
   
   
5. Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water
    
   
6. Complexes to improve oral absorption of poorly absorbable antibiotics
    
   
7. Suspension of sparingly water-soluble acidic drug

Drug Delivery System, Wound Dressing

1. Apparatus and method for detecting bacterial growth beneath a wound dressing
    
2. Method for accelerated wound healing using novel fibrous webbings
    
3. Hemostatic media
    
4. Method for treating wound, dressing for use therewith and apparatus and system for fabricating dressing
    
5. Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisions
    
6. Wound dressing, ingredient delivery device and IV hold-down, and method relating to same
    
7. Wound dressings, apparatus, and methods for controlling severe, life-threatening bleeding
    
8. Wound dressings with anti-microbial and zinc-containing agents
    
9. Polyurethane foam dressing with improved moisturization
    
10. Wound dressing
     
11. Wound alternative treatment system
     
12. Lactoferrin compositions and methods of wound treatment
     
13. Pain-sensitive therapeutic wound dressings
     
14. Absorbent polymer compositions, medical articles, and methods
     
15. Topical wound dressing and method of making same
     
16. Bioadhesive compositions and biomedical electrodes containing them
     
17. Intrinsically bactericidal absorbent dressing and method of fabrication
     
18. Bioabsorbable wound dressing
     
19. Hydrocolloid adhesive mass with improved resistance to deterioration of its absorption capacity after being sterilized by radiation
     
20. Honey based wound dressing
     
21. Fibrinogen bandages and arterial bleeding models and methods of making and using thereof
     
22. Composite dressings for the treatment of wounds
     
23. Bilayered collagen construct
     
24. Sterilizable paste product for topical application
     
    
25. Composition for arresting the flow of blood and method
     
    
26. Antimcrobial multi-layer island dressing

Drug Delivery System, Miscellaneous

1. Delivery of active agents using a chocolate vehicle
    
2. Ibuprofen composition
    
3. Method for controlling average pore diameter of porous body comprising apatite/collagen composite fibers
    
4. Application system for a plaster containing an active ingredient and a controlled-release agent for said active ingredient
    
5. Adhesion-preventing material and process for preventing adhesion
    
6. Use of autologous sediment from fluid aspirates as vehicles for drug delivery
    
7. X-ray guided drug delivery
    
8. Moisture curable materials for delivery of agents, methods, and medical devices
    
9. Abuse-resistant amphetamine prodrugs
    
10. Sustained release pharmaceutical compounds to prevent abuse of controlled substances
     
11. Methods and compositions for deterring abuse of opioid containing dosage forms
     
12. Intracorporeal medicaments for photodynamic treatment of disease
     
13. Analytical method for the determination of infant formula protein digestibility in vitro
     
14. Controlled release depot formulations
     
15. Particulate acellular tissue matrix
     
16. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
     
17. Fixed-dried platelets cross-linked to protein
     
18. Methods and compositions for deterring abuse of opioid containing dosage forms
     
19. Polymer blends that swell in an acidic environment and deswell in a basic environment
     
20. High functional water containing titanium and method and apparatus for producing the same
     
21. Water soluble multi-biotin-containing compounds
     
22. Pharmaceutical formulation containing bittering agent
     
23. Compartmentalized dosage form
     
24. Method for reducing malodor of chondroitin
     
25. Method for inducing therapeutically-effective proteins
     
26. Self-assembling colloidal carriers for protein delivery
     
27. Triblock copolymer hollow particles for agent delivery by permeability change
     
28. Methods and reagents for inhibiting proliferation of smooth muscle cells
     
29. Swallowing-assistive drink
     
    
30. Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering